Aphios® Pharma LLC
Our subsidiary Aphios® Pharma LLC is developing cannabis-based drugs for addiction, cancer pain and anxiety. Medical marijuana can help but its impact is very inconsistent and short-lived or acute. The marketplace is huge about $100 billion and poorly met with cannabis-based drugs that are designed for acute use and not adequate for chronic use. One such example is Epidiolex for childhood epilepsy developed by GW Pharma, approved by the FDA and recently sold to Jazz Pharmaceuticals for $7.6 billion. We differ from Jazz and other medical marijuana companies by using patented nanotechnology to sustain the release of cannabinoids in the body for treating chronic pain, anxiety and addiction.
Join Our Mailing List
Stay up to date with Aphios Pharma LLC by subscribing to our mailing list! Get the latest news on innovative therapies and advancements in pharmaceutical development.
Our Products
Developing Natural Solutions for Human Health®
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms, and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and CNS disorders such as Alzheimer’s Disease.
Our Technology
Taking Nature’s Wisdom to a Higher Level®
Using advanced scientific techniques, we are improving drug delivery, accelerating the drug discovery and manufacturing process, removing harmful pathogens from biologics and the human blood supply and working to provide a viable biofuel solution for the future.
Partnering Opportunities
Partnering for the Future of Human Health®
We are seeking partners and investors to further the development and utilization of our enabling technology platforms and enhanced therapeutic products. We are interested in working with individuals and companies dedicated to improving quality of life, maintaining health and treating unmet medical needs.
